These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 7959668)
1. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease. Eriksson ET; Schimmelpenning H; Aspenblad U; Zetterberg A; Auer GU Hum Pathol; 1994 Nov; 25(11):1228-33. PubMed ID: 7959668 [TBL] [Abstract][Full Text] [Related]
2. Immunoreactivity with monoclonal antibody A-80 and nuclear DNA content in benign and malignant human breast disease. Eriksson E; Schimmelpenning H; Silfverswärd C; Auer G Hum Pathol; 1992 Dec; 23(12):1366-72. PubMed ID: 1468773 [TBL] [Abstract][Full Text] [Related]
3. Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma. Schimmelpenning H; Eriksson ET; Falkmer UG; Azavedo E; Svane G; Auer GU Virchows Arch A Pathol Anat Histopathol; 1992; 420(5):433-40. PubMed ID: 1350695 [TBL] [Abstract][Full Text] [Related]
4. p53 protein expression and nuclear DNA content in breast intraductal proliferations. Schmitt FC; Leal C; Lopes C J Pathol; 1995 Jul; 176(3):233-41. PubMed ID: 7674086 [TBL] [Abstract][Full Text] [Related]
5. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. Ottesen GL APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968 [TBL] [Abstract][Full Text] [Related]
6. p53 mutations and expression in breast carcinoma in situ. Lukas J; Niu N; Press MF Am J Pathol; 2000 Jan; 156(1):183-91. PubMed ID: 10623666 [TBL] [Abstract][Full Text] [Related]
7. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer. Lisboa BW; Vogtländer S; Gilster T; Riethdorf L; Milde-Langosch K; Löning T Virchows Arch; 1997 Dec; 431(6):375-81. PubMed ID: 9428925 [TBL] [Abstract][Full Text] [Related]
8. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. Thor AD; Moore DH II; Edgerton SM; Kawasaki ES; Reihsaus E; Lynch HT; Marcus JN; Schwartz L; Chen LC; Mayall BH J Natl Cancer Inst; 1992 Jun; 84(11):845-55. PubMed ID: 1317462 [TBL] [Abstract][Full Text] [Related]
9. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. Done SJ; Arneson NC; Ozçelik H; Redston M; Andrulis IL Cancer Res; 1998 Feb; 58(4):785-9. PubMed ID: 9485035 [TBL] [Abstract][Full Text] [Related]
10. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer. Kang JH; Kim SJ; Noh DY; Choe KJ; Lee ES; Kang HS J Mol Med (Berl); 2001 Nov; 79(11):648-55. PubMed ID: 11715068 [TBL] [Abstract][Full Text] [Related]
11. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120 [TBL] [Abstract][Full Text] [Related]
12. Expression of c-erb B-2 protein and DNA ploidy in breast carcinogenesis. Schmitt FC; Figueiredo P; Lacerda M Arch Pathol Lab Med; 1995 Sep; 119(9):815-20. PubMed ID: 7668939 [TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma. Zhu XL; Hartwick W; Rohan T; Kandel R Mod Pathol; 1998 Nov; 11(11):1082-8. PubMed ID: 9831206 [TBL] [Abstract][Full Text] [Related]
15. High levels of p53 expression correlate with DNA aneuploidy in (pre)malignancies of the vulva. van der Avoort IA; van de Nieuwenhof HP; Otte-Höller I; Nirmala E; Bulten J; Massuger LF; van der Laak JA; Slootweg PJ; de Hullu JA; van Kempen LC Hum Pathol; 2010 Oct; 41(10):1475-85. PubMed ID: 20656324 [TBL] [Abstract][Full Text] [Related]
16. Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, non-invasive and invasive mammary carcinoma: an immunohistochemical study. Umekita Y; Takasaki T; Yoshida H Virchows Arch; 1994; 424(5):491-4. PubMed ID: 7913368 [TBL] [Abstract][Full Text] [Related]
17. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540 [TBL] [Abstract][Full Text] [Related]
18. [Microsatellite instability and allele-specific chromosome 3p deletion in breast cancer and precancerous lesions]. Fu Q; Yao GY; Tang XL; Chen LR; Zheng ZX Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):34-40. PubMed ID: 17575691 [TBL] [Abstract][Full Text] [Related]
19. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters. Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041 [TBL] [Abstract][Full Text] [Related]
20. Expression of tumor-associated antigen (DF3) in atypical hyperplasias and in situ carcinomas of the human breast. Ohuchi N; Page DL; Merino MJ; Viglione MJ; Kufe DW; Schlom J J Natl Cancer Inst; 1987 Jul; 79(1):109-17. PubMed ID: 3298784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]